source
- Amgen’s MariTide stands alone after obesity cull while analysts seek more M&AAmgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future bus…BioSpace · 9h ago↗ source
- Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPOAttovia Therapeutics has accreted a hefty $289 million from its IPO to power its anti-itch drugs through clinical development, marking another upsized listing in what has become a banner year for b…Fierce Biotech · 22h ago↗ source
- Merck’s anti‑TL1A antibody misses SSc‑ILD trial but hits primary endpoints in hidradenitis suppurativaMerck's anti‑TL1A monoclonal antibody, tulisokibart, was evaluated in two phase 2 studies. In the systemic sclerosis‑associated interstitial lung disease (SSc‑ILD) trial, the primary endpoint was…